Strides Pharma Reports Robust Q2FY27 Results Led by Ex-US Growth
Strides Pharma Science Ltd · Press Release · 30 Oct 2026, 12:24 am
Strides Pharma Reports Robust Q2FY27 Results Led by Ex-US Growth Strides Pharma Science posted a 17.1% YoY revenue growth to ₹14,297m for Q2FY27 ended 30th Sep'26, driven by Ex-US markets surging 31.0% YoY to ₹6,963m and surpassing US revenue of ₹6,855m (up 9.0% YoY). EBITDA rose 8.4% YoY to a record ₹2,509m, despite margins contracting 140 bps YoY to 17.6% due to freight and raw material pressures. Operational PAT increased 11.5% YoY to ₹1,358m, while reported PAT reached ₹1,341m. H1 net debt rose ₹2,114m amid higher inventory holding.
Original exchange filing (PDF)
More announcements from Strides Pharma Science Ltd
- Transcript of Earnings Call pertaining of Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2026 · 02 Nov 2026
- Audio Recording of Earnings Call pertaining to unaudited Financial Results for the quarter and half year ended September 30, 2026 · 30 Oct 2026
- Appointment of Mr. Biren Gabhawala (DIN:03091772) as a Non-Executive Independent Director of the Company with effect from November 1, 2026. · 30 Oct 2026
- Allotment of Equity shares pursuant to exercise of Stock Options. · 30 Oct 2026
- Earnings presentation for the quarter and half year ended September 30, 2026. · 30 Oct 2026
- Financial Results for the quarter and half year ended Sept 30, 2026 · 30 Oct 2026
- Strides Pharma Science Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 30 Oct 2026
- Earnings Call to discuss the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2026 · 30 Oct 2026
